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SOYFOODS, GLYCEMIC CONTROL AND DIABETES 
 
 
Summary 
Soy is characterised by a higher content of specific proteins and isoflavones. 
The question is to know if incorporation of soy foods in the diet may have a favourable effect, 
or not, on the risk of diabetes, on glycaemic index and insulinemic response, and which are 
the components involved in these effects. This litterature review analyse the epidemiological, 
clinical and experimental data for that question. Studies are in favour of a beneficial effect of 
soy on glycaemia, type 2 diabetes risk, and probably on complications of this disease. Its 
place in the diet should be examined. 
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Résumé 
Le soja est caractérisé par une teneur élevée en protéines spécifiques et en isoflavones. 
La question est de savoir dans quelle mesure l’incorporation d’aliments à base de soja peut 
avoir un effet favorable ou non sur le risque de survenue du diabète, sur l’indice glycémique 
et sur la réponse insulinémique, et quels sont les constituants qui pourraient en être 
responsables. Cette revue de la littérature analyse les données épidémiologiques, cliniques et 
mécanistiques relatives à cette question. 
Les études sont en faveur d’un bénéfice du soja sur la glycémie et le risque de diabète, voire 
les complications du diabète. Sa place dans l’alimentation mérite d’être examinée. 
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I. Introduction  
 
The role of soy in diabetes mellitus prevention and glycemic control has emerged through 
many facts since more than twenty years [1] : animal studies, epidemiological studies and 
mechanistic data on the stimulatory action of genistein on glucose uptake in vitro and in vivo 
[2] and on insulin secretory function of pancreatic β-cells [3]. Moreover genistein has been 
considered for many years as a potent agent against diabetic retinopathy through an inhibition 
of retinal neovascularization [4] and an anti-inflammatory effect [5] 
Diet is thought to play a key role in preventing the onset of type 2 diabetes mellitus (DM) and 
in helping to mitigate the risk of chronic diseases for which people with DM are at an 
increased risk.  For example, a meta-analysis by Lee et al. [6] that included 14 observational 
studies found that the pooled odds ratio (OR) for DM in vegetarians compared with non-
vegetarians was 0.726 (95% confidence interval [CI]: 0.608, 0.867).  Furthermore, subgroup 
analysis indicated that vegans had a much lower risk than vegetarians overall (0.596 vs 
0.726).  Importantly, the observed inverse association between a vegetarian diet and the risk 
of DM exists even after adjusting for body mass index (BMI) [7][8] 
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There are many components of a vegetarian diet that may contribute to lower risk of 
developing DM among vegetarians.  For example, vegetarians consume higher amounts of 
whole grains and less refined grain compared to nonvegetarians; observational studies show 
that these food groups are associated with lower and higher risks, respectively, of developing 
DM.  Another component common to vegetarian diet that may reduce DM risk is soy [9]. 
More than 100 years ago Friedenwald and Ruhrah [10] concluded that “The soy bean in some 
way causes a reduction in the percentage and total quantity of sugar passed in diabetic 
subjects on the usual dietary restrictions.”  Much more recently, Bhathena and Velasquez [1] 
concluded that emerging evidence suggests that diets rich in soy protein, at least in part 
because of the isoflavones it contains, can have beneficial effects on several aspects of DM.   
 
The purpose of this review is to examine the role of soyfoods and soybean components in the 
management of glycemic control and DM risk. 
 
II. Soy/Isoflavone Exposure and Risk of Diabetes: Epidemiology 
 
1) Dietary soyfoods intake or isoflavones exposure 
a) Multi ethnic studies 
A meta-analysis [11] which included seven cohort studies, found that the summary relative 
risk (RR) for developing DM was 0.87 (95% CI: 0.74–1.01) in all participants and 0.74 (95% 
CI: 0.56, 0.93) in women only when comparing high vs. low soy intake.  However, this 
analysis included a British [12] and Indian study [13], that reported legumes intake but not 
soy intake; furthermore, the former was published only as an abstract.   
Also included in the meta-analysis was a pooled analysis of three US cohort studies; the 
Nurses' Health Study (NHS, 1998-2012), the Nurses' Health Study II (NHSII, 1999-2013) and 
the Health Professionals Follow-Up Study (2002-2010) [14]. For reasons noted below (low 
consumption of soy), this pooled analysis [14] and another previously published [15] is 
questionable for providing insight about the relationship between soy and DM. The pooled 
analysis found that when comparing extreme quintiles of isoflavones intake, the hazard ratio 
(HR) was 0.89 (95% CI: 0.83, 0.96; p for trend = 0.009) [14]. 
 
Although these US results generally suggest soyfoods are protective against DM, there is an 
important caveat to consider.  Of the >163,000 participants in the three cohorts, only about 
5% consumed at least one serving of soyfoods per week.  Furthermore, the mean isoflavone 
intake of this group was only about 10-13 mg/d.  Although causality cannot be ruled out, it is 
unlikely that soy/isoflavone intake at this level could affect the development of DM.  Concern 
about the inability of Western epidemiologic studies involving the general population to 
provide meaningful insight into the health effects of soyfoods, because soy intake is so 
minimal, was first expressed more than a decade ago [16]. 
In contrast to these particular US results, soyfood intake was not protective against DM in the 
Hawaii component of the Multiethnic Cohort which is a prospective study (14 years of 
follow-up) performed among 29 141 Caucasian, 35 141 Japanese American and 10 484 
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Native Haiwaiian subjects [17]. Furthermore, this analysis suffers from the same limitation of 
low soy intake noted previously.  Even among Japanese Americans, mean soyfood intake was 
only 14.5 g/d.   
 
The authors of this study highlighted this limitation as a possible reason for their failure to 
find protective effects of soyfoods and compared intake in their study to a Japanese study 
[18]. 
b) Asian populations 
Indeed in this Japanese study, soyfood intake was protective against DM among overweight 
women [18]. Mean soy products and isoflavones intake in the Japanese study was about 90 
g/d and about 45 mg/d, respectively [18], which is about 6 times higher than the intake 
reported for Japanese Americans [16]. Among the 59 791 participants (43% men, 57% 
women, aged 45-75 y) a total of 1,114 new cases of type 2 DM were self-reported.  In this 
Japanese cohort study [18], although soy intake was unrelated to risk of DM among men and 
women overall, among overweight women (BMI ≥ 25) there were trends toward higher 
intakes of soy products and isoflavone intakes being associated with lower risk.   
Interestingly, in contrast to the results of Nanri et al. [18], in the Saku cohort study [19], soy 
intake was protective among overweight Japanese men (BMI ≥23.6), but not among normal-
weight men or women. In comparison to low soy-consumers (0-1x/wk), high soy-consumers 
(≥4x/wk) were 60% less likely to develop DM, fasting hyperglycemia or postload 
hyperglycemia (95% CI: 0.18, 0.92) over the 4-years follow period [19]. This cohort involved 
1,738 men and 1,301 women, aged 30–69 years.  
The first prospective study to examine the relationship between soy intake and DM risk was 
the Shanghai Women’s Health Study (SWHS), a population-based cohort of more than 64,000 
middle-aged Chinese women [20]. Dietary intake was assessed with a validated food-
frequency questionnaire at the baseline survey and at the first follow-up survey administered 
2-3 y after study recruitment. The multivariate-adjusted RR of DM for the upper quintile of 
compared with the lowest quintile was 0.62 (95% CI: 0.51, 0.74) for total legumes (peanuts, 
soybeans and other legumes) and 0.53 (95% CI: 0.45, 0.62) for soybeans.  However, the 
association between soy products (other than for soy drink) and soy protein consumption with 
DM was not significant although the trend was in that direction (p for trend = 0.13 for both 
food categories). 
 
Another large Asian cohort that examined the soy-DM connection is the Singapore Chinese 
Health Study (SCHS), which includes 43,176 Chinese men and women aged 45-74 y [21]. 
During an average follow-up of 5.7 y, 2,252 participants developed DM. After adjustment for 
potential confounders and BMI, consumption of unsweetened soy was inversely associated 
with DM risk.  HRs for DM across unsweetened soy intake categories (none, 1-4/month, 1-
2/week, 3-4/week, ≥5/week) were: 1.00 (reference), 0.81 (95 % CI: 0.67, 0.97), 0.76 (95 % 
CI: 0.63, 0.91), 0.76 (95 % CI: 0.63, 0.92), and 0.72 (95 % CI: 0.59, 0.89), respectively (p for 
trend, 0.015). Conversely, in multivariate models, consuming sweetened soybean drinks was 
positively associated with DM risk.  After full adjustment, there was also a marginally 
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significant inverse association between isoflavones intake and DM (HR for the fifth compared 
to the first quintile: 0.76; 95% CI: 0.58, 1.00; p for trend, 0.08).  
 
2) Plasma or urinary isoflavones concentration  
A nested case-control study among 1,111 type 2 diabetic pairs participating in the NHSI and 
NHSII found that when comparing extreme tertiles of urinary isoflavones, the odds ratio (OR) 
of DM were 0.71 (95% CI: 0.55, 0.93) for daidzein and 0.74 (95% CI: 0.56, 0.97) for 
genistein, although the test for linear trend was not significant for genistein (p for trend=0.03 
and 0.15, respectively) [15]. The inverse association of daidzein with DM risk was stronger 
among postmenopausal women who did not use hormone replacement therapy.   
However, a subsequently published nested case-control study within the SCHS that included 
564 DM cases and 564 matched controls failed to show that urinary isoflavone levels were 
related to DM risk [22]. More specifically, the multivariate-adjusted OR for DM were 1.00 
(reference), 0.76 (95% CI: 0.52, 1.11), 0.78 (95% CI: 0.53, 1.14) and 0.79 (95% CI: 0.54, 
1.15) across quartiles of urine isoflavones (p for trend=0.54).  The mean age of the 
participants at the time of urine collection was 59.8 years, and the average interval between 
urine collection and DM diagnosis was 4.0 years.  A possible caveat about this study is that 
because the half-life of isoflavones is only about 6-8 hours, morning urinary isoflavones 
excretion can be greatly affected by the timing of prior isoflavones intake and therefore, may 
not be a good measure of overall long-term exposure [23]. 
Finally, there are two case control studies, one from Korea [24] and one from Vietnam [25], 
both of which provide some support for the protective effects of soyfoods, but the former 
comes with an important caveat.  A nested case-control study comprised of 693 cases (316 
women and 377 men) and 698 matched controls (317 women and 381 men) within the Korean 
Genome and Epidemiology Study found that in women, compared with the lowest quartile of 
plasma concentration of genistein, the highest quartile exhibited a significantly decreased risk 
of DM (OR 0.58, 95% CI: 0.35, 0.95) [24]. However, when stratified by equol-producing 
status in women, genistein was protective only among equol producers and in men 
isoflavones concentrations were not associated with risk of DM, regardless of equol-
producing status. In Vietnam, a hospital-based case-control study involving 599 newly 
diagnosed diabetic cases (age 40-65 years) and 599 hospital-based controls found higher 
intake of total soyfoods was significantly associated with a lower risk of DM [25] The 
adjusted OR for the highest versus the lowest intake was 0.31 (95% CI: 0.21, 0.46; P<0.001). 
An inverse dose-response relationship of similar magnitude was also observed for total 
isoflavones intake (OR: 0.35; 95% CI: 0.24, 0.49; p<0.001). In addition, inverse associations 
of specific soyfoods (soy drink, tofu and mung bean sprout) and major isoflavones (daidzein, 
genistein and glycitein) with the DM risk were evident.  
 
Recently a cross-sectional study of 3 314 subjects aged 18-79 years, was performed in 
Beijing, China in 2019 [26]. After adjustment soy products consumption was inversely 
associated with type 2 diabetes risk: OR for DM was 1,00 (reference), 0,82 (95 % CI: 0,63 – 
1,07), 0,60 (95 % CI: 0,39 – 0,94) respectively across soy products consumption frequencies 
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(monthly, weekly, daily) (p for trend 0,033) and with impaired fasting glucose (IFG): OR for 
IFG 1,00 (reference), 0,87 (95 % CI: 0,66 – 1,15), 0,62 (95 % CI: 0,385 – 0,985) respectively 
(p for trend 0,046). 
3) Summary of the epidemiologic data 
Case-control and/or cohort studies examining the relationship between soy and DM have been 
conducted in China [20], Singapore [21][22], Japan [18][19], Vietnam [25], Korea [24] and 
the United States [14][15][17]. The US data provide some support for the protective effects of 
soy against the development of DM but as noted, they are of doubtful relevance because of 
the low soy intake of Americans. 
 
Among the ethnic Chinese, soy intake was protective against DM in a Shanghainese cohort 
[20]  and in Beijing population [26] whereas a Singaporean cohort, this was true for 
unsweetened but not sweetened soy drink [21] and urinary isoflavones were found to be 
unrelated to risk in a nested case-control study from this cohort [22]. One Japanese cohort 
found that soy intake was protective among overweight women but not men or normal-weight 
women [18] whereas another found that, soy intake was protective against overweight men 
but not among women or normal-weight men [19]. Finally, a Korean case-control study found 
soy intake was protective only among equol producers [24] whereas a Vietnamese study 
found soy intake was markedly protective in both men and women [25]. 
The differing amounts of soy consumed among the populations studied could be key.  For 
example, in the Shanghainese cohort, which found soy intake to be very protective, median 
soy protein intake among those in the 5th quintile was 15.3 g/d [20], whereas in the 
Singaporean cohort, the 5th quintile consumed only 10.9 g/d [21]. 
Although some results are discordant according to the weight status, globally there are no 
negative studies and almost all show a protective effect of soyfoods and isoflavones intake (or 
markers of isoflavones intake) against DM. 
 
III. Glycemic index and glycemic load of soyfoods 
 
Unlike most beans which derive the majority (~70%) of their calories from carbohydrate, only 
about 30% of the energy from soybeans comes from this macronutrient [27][28]. This 
distinction is important because after a recent comprehensive review of the literature, 
Feinman et al. [29] concluded that “The benefits of carbohydrate restriction in DM are 
immediate and well documented.”  Although very recently published research provides only 
very modest support for the benefits of low-carbohydrate diets over low-fat diets, at the very 
least these data show the former are viable options for patients with DM [30][31]. Recently a 
meta-analysis of randomized controlled trials on the effect of the amount of carbohydrate in 
the management of type 2 diabetes has shown that a moderate low-carbohydrate diet more 
beneficial on HbA1c than a normal carbohydrate diet [32]. Furthermore, not only are soybeans 
low in carbohydrate, but about half of the carbohydrate in soybeans is comprised of 
oligosaccharides (primarily stachyose and  raffinose) which are very poorly absorbed [33], 
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and which were recently shown to favorably affect insulin and glucose levels in pregnant 
women with gestational diabetes mellitus [34]. 
Not surprisingly, many soyfoods have a very low glycemic index (GI).  Even before Jenkins 
et al. [35] coined this term in 1981, this research group had established that soybeans had a 
low GI [36]. In fact, of the 24 foods they tested, which included eight legumes, soybeans had 
the lowest GI [36]. It was soon determined that a number of factors could contribute to the 
low GI of soybeans unrelated to carbohydrate content [37][38].  For example, Thompson et al. 
[37] showed a strong inverse correlation between the intake of polyphenols from foods and 
the GI when tested in both healthy and diabetic individuals.  Of the foods they examined, 
legumes in general and soybeans in particular, had the highest polyphenols concentration.  
 
Soy fiber may also play a role in the low GI of soybeans [39][40][41][42][43][44]  although 
not all studies suggest this is the case [45][46].  Soy fiber is less effective in reducing GI than 
gel-forming fibers such as guar gum, beta glucans or pectin which is not surprising because 
soy polysaccharide is mostly insoluble fiber.  On the other hand, insoluble fiber [47] has been 
linked with increased insulin sensitivity and decreased risk of DM [48].  The low GI of 
soybeans was emphatically illustrated in 1995 when the first comprehensive list of the GI of 
foods was published [49].  However, that list also included a tofu-based dessert with a high GI 
because of the amount of sugar that had been added to it [50].   
 
As a metric the GI underestimates the advantages of soybeans and soy products for 
controlling glucose levels because it fails to consider the low carbohydrate content of 
soybeans.  A superior measure is arguably the glycemic load (GL) which reflects both the GI 
and carbohydrate content of foods.  In 2002, Foster-Powell et al. [51] published a 
comprehensive list of the GI and GL of foods.  Soybeans had a GL of 1, indicating it was both 
low in carbohydrates and the carbohydrates in it had a low GI.  In comparison, the GL for 
other beans ranged from 2 (boiled peas) to 19 (pressure cooked haricot and navy beans). 
Glycemic index should be considered at the level of the food and not as a characteristic of a 
type isolated carbohydrate. Indeed, consumers eat foods, not carbohydrates; and foods 
containing the same type of carbohydrates can have different glycemic index, depending on 
their content in other nutrients, the structure of the matrix, the process they are submitted to.   
 
Quite a few other soy-containing products were included in the list but were part of a mixed 
food or beverage, so it is difficult to gleam specific information about soy per se in these 
cases.  Several flavored soy drinks were listed as having GLs between 6 and 8 and a soy 
yogurt and tofu-based frozen desert had GLs of 13 and 10, respectively [51].  Not 
surprisingly, as shown by Torres y Torres et al. [52] in the case of soy beverages the non-soy 
components, especially the addition of sugars, will greatly influence the GI and GL.  These 
authors found that soy beverages had a low or moderate GI, depending upon the presence of 
other compounds like carbohydrates and fiber. Consumption of soy beverages with low 
concentrations of carbohydrates produced the lowest insulin secretion. Therefore, these 
products can be recommended for obese and diabetic patients. More recently, Serrano et al. 
[53] attributed the very low GI of soy drink (2.7 g sugar/100 ml) partly to a relatively low 
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carbohydrate absorption and partly to components in soy increasing incretin levels.  Incretins 
are hormones that are released from the gut into the bloodstream in response to ingestion of 
food that modulates insulin response [54]. 
 
IV. Effects of co-ingestion of soy and carbohydrate on glycemic response 
 
Several studies have examined the impact of soy on the glycemic response of other foods, 
which is an important consideration since foods are rarely eaten in isolation.  Recently, Law et 
al. [55][56] conducted two studies comparing the effects of different beverages on the 
glycemic response of cereal.  In the first study, thirty six healthy males and females consumed 
non isocaloric amounts (250 ml) of four test beverages (almond beverage, soy beverage, 1 % 
fat milk, yogurt beverage): the area under the curve (AUC, mmol/min/L) for glucose 120 
minutes post ingestion was lowest following the soy beverage compared with all treatments 
but was not significantly different from milk [55].The AUC insulin was lowest for almond 
milk and the soy drink and the values for both differed significantly from milk and yogurt. In 
the second study, thirty participants received in random order 250 mL of 2% fat milk and soy 
beverage, 175 g of 2% Greek yogurt, and 30 g of Cheddar cheese consumed as part of an 
isocaloric (380 kcal) meal with bread and jam [56] providing respectively 64g, 71g, 60g, 55g 
of carbohydrate for each meal.  Water alone served as the energy-free control. Cheese and 
yogurt resulted in lower post-treatment blood glucose than milk and soy beverage when 
consumed with carbohydrate (p < 0.0001), but no differences among any treatments were 
observed post-meal (after consuming a meal 3 hours later) and the treatments led to similar 
insulin concentrations.  
 
In a study with twenty five healthy subjects in a randomized trial by Veldhorst et al.[57], 500 
ml 2% fat milk lowered the glucose response following a meal more than soy drink even 
though the former had a higher sugar content and also a slightly higher protein content (18 vs. 
14 g).  The lower glucose response could have been because milk protein may be more 
insulinotropic than soy protein [57]. On the other hand, although Sun et al.[58] found  in a 
cross-over study with twelve healthy male that soy drink and cow’s milk similarly affected 
the glycemic response to bread; but co-ingesting soy drink with bread increased insulin 
response and insulinemic index significantly compared to co-ingestion of dairy milk. A 
randomized study on twelve healthy male has shown that soy drink and cow’s milk might be 
equally on glycemic regulation although through different mechanisms [59]. Plasma amino 
acid and incretins such as GIP may be involved in the hyperinsulinemia observed after soy 
milk meals. However higher plasma branched chain amino acid concentration and GLP1 
release may be responsible for the reduced glycaemia after cow milk consumption and 
delaying gastric emptying.  
 
Finally, other studies have found little difference in the glucose response to a meal when 
comparing soy protein with animal protein including milk protein [60][61]  although one 
study found that a casein-enriched lunch delayed glucose and insulin responses for 1.5 h, 
compared with soy protein, probably due to a lag in gastric emptying [62].  
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In summary, some data suggest there is a favorable effect of soy beverage on glycemic 
response. However there is still a gap due to the lack of studies comparing food with high GI 
only to food with high GI plus soy food. 
 
V. Effects of soybean components on insulin and glucose levels 
 
1) Isoflavones   
 
Four meta-analysis (or subsets within the analysis), which in total included 25 studies, that 
evaluated the impact of isoflavones on glycemic control have been published.  The specific 
analysis included 7 [63], 9[64], 10 [65] and 17 studies [66] which do not have the same 
design. For example, the analysis by Liu et al.[63] included only studies that intervened with 
the isoflavone genistein (10 studies, 696 participants) whereas Ricci et al.[64] included only 
studies involving non-Asian women (9 studies, 405 women and 389 controls). Moreover in 
the same meta-analysis, some studies are performed with total isoflavones, other with 
genistein or a mixture (table 1). 
 
As can be seen from the table I nearly all studies involved postmenopausal women and only 
seven of the 25 studies involved women with abnormal glycemic control including women 
with elevated fasting glucose, insulin resistance, metabolic syndrome or DM.  The vast 
majority of the isoflavones were administered in tablet form and compared to placebo 
whereas three studies intervened with soy protein containing different amounts of isoflavones 
[67-69], one study used a cereal bar fortified with isoflavones [70] and one compared soy 
protein containing isoflavones with casein [67], even though this experimental design does 
not allow outcome differences between groups to be attributed to isoflavones. The dosage of 
isoflavones ranged from a low of 40 mg [68]  to a high of 132 mg/d [69].  Seven trials 
intervened with genistein only, eleven trials intervened with a mixed isoflavones wherein the 
supplement contained an amount of genistein similar to or greater than that of daidzein; in 
five trials daidzein was the predominant isoflavone and genistein was present in lower 
amounts than glycitein, in one glycitein was the predominant isoflavone and in one study the 
composition of the isoflavone was not identified. 
 
Ricci et al.[64] concluded that isoflavones overall had no effect on glycemic control but based 
on the results of three studies concluded that genistein alone likely favorably did.  In 
agreement, in the 2011 meta-analysis by Liu et al. [65], no effect of isoflavones on glycemic 
control was noted.   
 
However, it should be emphasized  that because the three genistein-only studies cited above in 
the analysis by Ricci et al. [64], led to significant heterogeneity in fasting glucose 
concentrations, they were excluded from this analysis.  Not surprisingly, in the 2017 analysis 
by Liu et al. [63], which involved 670 participants all of which were involved in studies 
intervening with genistein only, it was found that genistein significantly lowered elevated 
glucose levels and increased insulin sensitivity in postmenopausal women.  
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Finally, there is the meta-analysis by Fang et al.[66], which included 17 studies.  The results 
showed that overall in response to isoflavones blood glucose and insulin levels were lower in 
comparison to the placebo group.   However, it was concluded that “genistein alone played an 
important role in improving glucose metabolism …”These findings are not surprising because 
of the 17 studies, six intervened with genistein only.  Compared to the analysis by Liu et al. 
[63] only the Turkish study by Kaygusuz et al. [70] was not included in the analysis by Fang 
et al.. [66] 
 
In conclusion, the evidence shows that genistein favorably affects glycemic control. With one 
exception these studies were conducted in Italy by one research group and involved the use of 
54 mg genistein delivered in aglycone form [70].  No obvious explanation for the striking 
performance of these genistein-only studies has been offered.  It may be that when presented 
in aglycone form Cmax genistein levels are higher in comparison to when this isoflavone is 
ingested in glycoside form and as a result, biological processes related to glycemic control are 
favorably affected. 
2) Soy protein   
 
Two meta-analyses were identified that evaluated the effects of soy protein on glycemic 
control over a period of many weeks (table 2).  One of these included eight studies and 
involved 183 patients with DM [71]. However, of the eight studies only four reported serum 
fasting glucose concentration in a way that permitted pooling of data.  The pooled weighted 
mean differences for fasting glucose, insulin and HbA1C were -0.68 mmol/L (95% CI: -1.78, 
0.42), -0.77 pmol/L (95% CI: -4.16, 2.62) and -0.09% (95% CI: -0.50% to 0.31%).  Not 
surprisingly, given that none of these findings were statistically significant, the authors 
concluded that soy wouldn’t affect glycemic control.   
 
In contrast to the conclusions by Yang et al., [71] on the basis of their 2016 meta-analysis, 
Zhang et al. [83] concluded that soy protein favorably affects fasting plasma glucose 
[weighted mean difference (WMD), -0.207; 95% CI, -0.374 to -0.040; p=0.015], fasting 
serum insulin (WMD, -0.292; 95% CI, -0.496 to -0.088; p=0.005) and homeostasis model of 
assessment for insulin resistance index (WMD, -0.346; 95% CI, -0.570 to -0.123; p=0.002) 
compared with a placebo control group, in patients with DM or the metabolic syndrome.  
However, their analysis included only 5 studies.  Furthermore, one of the five trials intervened 
with peptides derived from black soybeans [79] and two intervened with soynuts in place of 
red meat [74][75]. Obviously, the latter two studies don’t allow the outcome differences to be 
attributed specifically to soy protein and the results of the former are not necessarily 
applicable to the ingestion of soy protein.   
 
In summary, relatively few studies have compared the effects of soy protein with a control 
protein on glycemic control.  Based on the available data soy protein may favorably affect 
glucose levels but the effect is modest and the data too limited to draw definitive conclusions. 
 
3) Soy peptides   
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Soy is also an interesting source of bioactive peptides which are able to have physiologic 
actions against glucose homeostasis and insulin metabolism. A recent review [84] has 
summarized the in vitro and in vivo studies of soy hydrolysates peptides. In vitro results show 
that soy hydrolysates peptides obtained after hydrolysis by specific enzymes and some 
identified peptides can improve insulin sensitivity, inhibit DPP-IV, increase glucose intake in 
muscle and liver, and reduce lipid accumulation and inflammation in adipose tissue. In vivo 
results, although scarce, show that soy hydrolysates and soy peptides can potentially reduce 
tissue fat accumulation and increase fat excretion. Moreover the soy peptides aglycin is 
resistant to gastrointestinal digestion and can be absorbed intact in mice. Nevertheless, only a 
few studies were performed to test soy hydrolysates and peptides as antidiabetic agents. 
 
VI. Effects of soyfoods on diabetes-related complications 
 
As noted at the onset two of the main medical complications of DM are CVD and renal 
failure.  It is far beyond the scope of this review to address the impact of soyfoods on these 
two diseases. it would be an oversight not to at least mention that intriguing data suggest soy 
can help to reduce risk of developing, and possibly be useful in the management of CVD and 
renal disease. 
For example, the most recently published meta-analysis of the clinical data shows that soy 
protein statistically significantly lowers low-density lipoprotein cholesterol (LDL-C) and that 
whole soyfoods lower LDL-C more than isolated soy protein [85]. Recently a meta-analysis 
of 46 controlled trials identified by the Food and Drug Administration demonstrates that soy 
protein reduces LDL concentration by approximately 3-4 % in adults [86]. Soyfoods can also 
lower cholesterol levels when replacing sources of protein commonly consumed by 
Westerners because of the favorable change in the fatty acid content of the diet [87].  Whole 
soyfoods provide ample amounts of linoleic acid [88] which, when replacing saturated fat in 
the diet, reduces risk of developing CVD [89].  There may be components of soybeans, such 
as the isoflavones, that favorably affect other non-lipid CVD risk factors [90][91][92][93]. 
Recently a randomized controlled clinical trial on 75 subjects with type 2 diabetes has 
analyzed the effect of the substitution of red meat with soy-bean or not-soy legumes on 
inflammatory and oxidative stress markers [94]. In these 8 weeks parallel trial 2 servings red 
meat a day, 3 days / week were substituted by one cup of soy beans or one cup of legumes. 
Soy bean but not non-soy legumes reduce significantly serum CRP with no effect on 
oxidative marker (serum malondialdehyde). Thus, soyfoods potentially reduce risk of 
developing CVD through multiple mechanisms. 
In addition, some evidence suggests that soy protein places less stress on renal function in 
comparison to animal protein [95].  Furthermore, meta-analyses of the clinical data indicate 
that soy protein helps to maintain favorable serum creatinine and phosphorus levels [96][97] 
and possibly also decreases inflammation (as assessed by C-reactive protein) and proteinuria 
in chronic kidney disease.  All of these effects are to the benefit of individuals at risk of 
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developing, and those with existing kidney disease, the incidence of which has increased 
dramatically over the past 20 years as a result of the increased prevalence of DM.  
 
VII. Overall conclusions 
Some epidemiological data show that higher soy foods consumption and isoflavones intake is 
associated with a lower risk of developing type 2 diabetes. The mechanism is discussed and 
may involve the low glycemic index of soyfoods. Some data exist in support of the 
isoflavones genistein increasing insulin sensitivity and lowering elevated glucose levels. The 
role of soy protein on glucose metabolism is inconsistent, but some data suggest that soy 
bioactive peptides may have a favorable role on glucose homeostasis. But one must take 
account firstly the specificity of the traditional form of consumed soyfoods in Asian 
populations principally as fermented tofu and miso, secondly the fact that soy beverages in 
western countries contain added sugar, thirdly the complexity of soyfoods and so the 
importance of whole soyfoods [65] because several components of soyfoods may affect the 
risk of type 2 diabetes or of glucose tolerance. 
Moreover it is important to consider that a part of the beneficial effect of soyfoods 
consumption may be due to the global diet: indeed in western countries soyfoods are very 
often included in a vegetarian diet. 
Finally, as briefly discussed, independent of their potential effects on glycemic control and 
DM risk, soyfoods may be of help in alleviating common medical complications of DM such 
as CVD and renal disease.   
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Table 1.  Studies included in meta-analyses evaluating the effects of isoflavones on long-term glycemic control 
 
Author/year/reference Location 
Isoflavone 
compositiona 
Dose  
(mg/day) 
Participants 
Diabetic, MetS,b 
↑ FGc or IRd 
Meta-analyses 
Ricci, 
2010 
Liu,  
2011 
Fang,  
2016 
Liu,  
2017 
Atteritano, 2007/[98] Italy G 54 Postmenopausal No x  x x 
Aubertin-Leheudre, 2008/ 
[68] 
Italy D>Gly>G 70 Postmenopausal No x x x  
Bakhtiary, 2011/[99] Iran G>D>Gly 117 Older Yes   x  
Chan, 2008/[100] Hong Kong NI 80 Older men/women ~50%  x   
Charles, 2009/[101] USA G=D>Gly 96 Postmenopausal No x x x  
Choquette, 2011/ [102] Canada D>Gly>G 70 Postmenopausal No   x  
Colacurci, 2005/[103] Italy G=D 120 Postmenopausal No x  x  
Crisafulli, 2005/[104] Italy G 54 Postmenopausal No   x x 
Duncan, 1999/[105] USA G>D>Gly 10, 64, 128 Premenopausal No  x   
Duncan, 1999/[69] USA G>D>Gly 7, 65, 132 Postmenopausal Yes  x   
Garrido, 2006/[106] Chile D>Gly>G 100 Postmenopausal No x x x  
Gonzalez, 2007/ [107] UK G>D>Gly 132 Postmenopausal Yes  x   
Hall, 2006/[108] Europe G>D>Gly 50 Postmenopausal No  x   
Han, 2002/[109] South Korea G>D>Gly 100 Postmenopausal No x  x  
Ho, 2007/[110] Hong Kong D>Gly>G 40, 80 Postmenopausal No  x x  
Irace, 2013/ [91] Italy G 54 Postmenopausal Yes   x x 
Kaygusuz, 2010/[70] Turkey G 50 Postmenopausal No    x 
Khaodhiar, 2008/[111] USA D>Gly>G 40, 60 Postmenopausal No x  x  
Llaneza, 2010/[112] Spain G>D>Gly 40 Postmenopausal Yes   x  
Llaneza, 2012/[113] Spain G>D>Gly 80 Postmenopausal No   x  
Marini, 2010/[114] Italy G 54 Postmenopausal No   x x 
Nikander, 2004/[115] Finland Gly>D>G 114 Postmenopausal No  x `  
Sites, 2007/[67] USA G=D>Gly 96 Postmenopausal No x    
Squadrito, 2013/ [84] Italy G 54 Postmenopausal Yes   x x 
Villa, 2009/[116] Italy G 54 Postmenopausal Yes x  x x 
aRelative proporition of isoflavones bMS, metabolic syndrome cFasting glucose dIR, insulin resistance 
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Table 2. Studies included in meta-analyses evaluating the effects of soy protein on  
long-term glycemic control 
 
Author/year/(reference) Soy protein dose 
(g/d) 
Yang et al., 2011 
(all diabetics) [77] 
Zhang et al., 
2016 [89] 
Anderson, 1998/ [72] 111 X  
Azadbakht, 2003/ [73] 20 X  
Azadbakht, 2007/ [74] 30  X 
Azadbakht, 2008/ [75] 20 X X 
Gobert, 2010/ [76] 40 X  
Hermansen, 2001/ [77] 50 X  
Jayagopal, 2002/ [78] 30 X  
Kwak, 2010/ [79] 4.5  X 
Liu, 2010/ [80] 15  X 
Pipe, 2009/[81] 40 X  
Teixeira, 2004/ [82] 0.5 g/kg bw X X 
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